Benefits
Memory and cognitive performance
Cognivia demonstrated significant working memory and accuracy improvements in a 29-day RCT in healthy adults aged 30-60, with effects strongest at day 29 indicating cumulative benefit. A second crossover study showed acute benefits on numeric working memory and reaction time during physical exercise. Generic Salvia officinalis extract has also shown acute memory enhancement in healthy adults across multiple smaller crossover trials.
Cognitive scores in an older dementia population (generic sage)
A 16-week RCT in mild-to-moderate Alzheimer's patients found Salvia officinalis ethanolic tincture significantly improved cognitive function on the ADAS-cog scale and Clinical Dementia Rating versus placebo. This is a single small trial (n=42) in a disease population and does not establish that sage treats, prevents or slows Alzheimer's disease. This evidence is for generic Salvia officinalis tincture, not the Cognivia formulation.
Mood effects reported for generic sage (not Cognivia)
Sage supplementation has shown significant mood improvements in healthy adults, increasing alertness, calmness, and contentedness on standardized mood scales, with reduced anxiety at some doses. Effects are attributed to a combination of cholinergic enhancement and GABA-A receptor modulation by sage monoterpenes. Note: most mood evidence is for generic Salvia species, not the Cognivia formulation specifically.
Antioxidant and anti-aging neuroprotection
Carnosic acid and carnosol from sage are extremely potent lipophilic antioxidants that cross the blood-brain barrier and protect neuronal lipid membranes from oxidative damage. These neuroprotective polyphenols complement the acetylcholinesterase inhibition mechanism, providing both symptomatic and protective benefits for cognitive aging.
Mechanism of action
Acetylcholinesterase inhibition
Sage extract — particularly its monoterpene fraction (1,8-cineole, α-thujone, camphor) — inhibits acetylcholinesterase in a dose-dependent, reversible manner. This increases synaptic acetylcholine availability in hippocampal and cortical circuits governing learning and memory, explaining the acute memory improvements observed within 1 hour of supplementation.
Nicotinic and muscarinic receptor binding
Sage constituents directly bind nicotinic (nAChR) and muscarinic (mAChR) acetylcholine receptors — both the inhibitory (M2/M4) and excitatory (M1/M3) subtypes — producing net cholinergic enhancement through receptor activation alongside enzyme inhibition. This dual mechanism explains effects broader than acetylcholinesterase inhibition alone.
GABA-A receptor modulation and anxiolytic activity
Sage monoterpenes (particularly linalool and borneol) act as positive allosteric modulators at GABA-A receptors in vitro and in animal models — the same receptor class targeted by benzodiazepines, but with lower affinity and without dependency risk. This GABAergic mechanism may contribute to the calming effects observed in some sage trials, though direct evidence in humans is limited.
Clinical trials
Randomized, double-blind, placebo-controlled, parallel-group trial of Cognivia® (600 mg/day, containing 400 mg Salvia officinalis polyphenols + 50 µL Salvia lavandulaefolia essential oil) vs. placebo in 94 healthy adults aged 30–60 for 29 days. Conducted at Northumbria University, sponsored by Nexira.
94 healthy adults aged 30–60 (69 female, 25 male). 29-day intervention with assessments at 120 and 240 min post-dose on day 1 and day 29.
Cognivia® produced consistent, significant benefits on working memory and accuracy outcomes (Corsi Blocks, Numeric Working Memory, Name to Face Recall) both acutely (within day 1) and chronically (after 29 days). The chronic cumulative benefit was strongest, suggesting sustained engagement of cholinergic and antioxidant pathways. Well-tolerated with no significant adverse events.
Randomized, double-blind, placebo-controlled, crossover trial of Cognivia® (600 mg single dose) vs. placebo in healthy active adults during intense physical activity. Conducted by INSERM (French National Institute of Health and Medical Research), published in Frontiers.
26 trained athletes in a randomized, double-blind, placebo-controlled crossover trial. A single dose of the Salvia officinalis plus Salvia lavandulaefolia combination was taken about 2 hours before a fatiguing cycling task, versus placebo on a separate session. Cognition was tested at four points across warm-up, exercise and recovery.
With the sage combination, reaction time was shorter (P=0.023), backward digit-span memory score was higher (P=0.044), and rated perceived exertion was lower (P=0.002) than with placebo during the cycling task. Acute single-dose effects only; no repeated dosing was tested. Industry-funded (Nexira).
Randomized, double-blind, placebo-controlled trial of Salvia officinalis ethanolic extract tincture (60 drops/day) vs. placebo in 42 patients with mild-to-moderate Alzheimer's disease for 16 weeks. Note: this trial used generic Salvia officinalis extract, not Cognivia® specifically.
42 patients with mild-to-moderate Alzheimer's disease. 16-week intervention.
Sage extract produced significantly better cognitive function on the ADAS-cog scale and Clinical Dementia Rating compared to placebo (P=0.03 for ADAS-cog, P<0.003 for the CDR sum-of-boxes). Agitation was somewhat less frequent than in the placebo group. Well tolerated over 16 weeks. This is a single small trial (n=42) in an Alzheimer's population and does not establish sage as a treatment for the disease.